Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726383 · ClinicalTrials.gov registry record · Phase 2
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
A Phase 2 study of Osteogenic Sarcoma Recurrent, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT05726383: Recruiting Phase 2 study of Osteogenic Sarcoma Recurrent, sponsored by Hackensack Meridian Health.
NCT05726383 is a Phase 2 study of Osteogenic Sarcoma Recurrent that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05726383, a Phase 2 study of Osteogenic Sarcoma Recurrent, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions. The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.
Primary Outcome
To estimate the event free survival for pediatric, adolescent and young adult patients with relapsed resectable osteosarcoma who are receiving treatment with subcutaneous Iscador® P following complete resection of all disease.
Conditions Studied
Interventions
- DRUG Iscador*P
Study Locations (2)
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- M.D. Anderson Children's Cancer Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-05-14 |
| Est. Completion | 2027-05-11 |
| Phase | Phase 2 |
What NCT05726383 shows while recruiting
NCT05726383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Osteogenic Sarcoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Iscador*P is the first listed.
NCT05726383 reports a single indexed study location in New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT05726383 about?
NCT05726383 is a clinical study titled "Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma". This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid t...
What is the current status of trial NCT05726383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-05-14. Estimated completion is 2027-05-11.
What conditions does trial NCT05726383 study?
This clinical trial studies the following conditions: Osteogenic Sarcoma Recurrent.
What interventions are being tested in trial NCT05726383?
The interventions under investigation include: Iscador*P (DRUG).
Who is sponsoring clinical trial NCT05726383?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726383 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05726383's enrollment target sits among peer trials
32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI